The Burrill Report


The Burrill Report (April 16, 2012) What's Ahead for Biotech Stocks (.MP3,11.65 Mb)

Biotech stocks got off to a blazing start in the first quarter as the sector seemed ready to put the ugliness of the second half of 2011 behind it as M&A deals and positive clinical trial results helped lift the sector. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about the winners and losers, what drove the activity, and what to be watching in the second.

April 13, 2012
http://www.burrillreport.com/article-whats_ahead_for_biotech_stocks_.html